You are here:Home-Inhibitors & Agonists-Antibiotics and Antivirals-Arenavirus

Request The Product List ofArenavirus Arenavirus

Arenaviruses are enveloped viruses with a bisegmented negative-strand RNA genome. Each genome segment, large (∼7.3 kb) and small (∼3.5 kb) uses an ambisense coding strategy to direct synthesis of two polypeptides in opposite direction, separated by a noncoding intergenic region (IGR). The S segment encodes for the viral nucleoprotein (NP) and the glycoprotein precursor (GPC), L segment encodes the viral RNA-dependent RNA polymerase (L polymerase) and the matrix Z protein.

Several arenaviruses cause hemorrhagic fever (HF) disease in humans and pose important public health problems in regions where these viruses are endemic. Lassa virus (LASV) infects several hundred thousand people yearly in West Africa, resulting in a high number of Lassa fever cases that are associated with high morbidity and mortality. Likewise, Junin virus (JUNV) causes Argentine HF, a severe illness endemic to Pampas in Argentina. Moreover, mounting evidence indicates that the worldwide-distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen of clinical significance. In addition, several arenaviruses, including LASV, JUNV, and LCMV, pose a credible biodefense threat.




1. Cao W, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science. 1998 Dec 11;282(5396):2079-81.

2. Ngo N, et al. Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of ArenavirusMultiplication. J Virol. 2015 Nov;89(21):10924-33.

3. Shankar S, et al. Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol. 2016 Jul 11;90(15):6799-807.

Cat. No. Product Name CAS No. Information



ST-193 (ST193) is a potent, selective, broad-spectrum arenavirus entry inhibitor with IC50 of 1.6 nM against LASV pseudotypes, targets arenavirus envelope glycoprotein; Also inhibits pseudotypes generated with other arenavirus envelopes with IC50 of 0.2-12 nM, but exhibited no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus LCMV or the unrelated G protein from vesicular stomatitis virus (IC50>10 uM); exhibits antiviral activity against Lassa virus (LASV) in a guinea pig model (i.p.).



1450929-77-7 LHF-535 (LHF535, LHF 535) is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein, exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses with IC50 of 0.1-0.3 nM; LHF-535 has sub-nanomolar potency against the viral envelope glycoproteins from all Lassa virus lineages, with the exception of the glycoprotein from the LP strain from lineage I, which was 100-fold less sensitive than that of other strains; potently inhibited Junín virus, but not Candid#1 in virus-yield reduction assays; protects mice in a lethal Tacaribe virus model at 10 mg/kg.

Other Indication

Phase 1 Clinical


LASV inhibitor 3.3

554438-52-7 LASV inhibitor 3.3 (LAMP1 inhibitor 3.3) is a specific inhibitor of Lassa fever virus (LASV, IC50=1.8 uM), inhibits LASV GP-mediated infection and cross-links to the LASV receptor, LAMP1, in cells; does not inhibits the GP-mediated infection of LCMV, LuJo virus (LUJV) or Junin virus (JUNV), Ebola virus (EBOV) or vesicular stomatitis virus (VSV); inhibits LAMP1 binding to LASV GP, which is cholesterol-dependent and sensitive to 3.3 inhibition; LASV inhibitor 3.3 is a competitive inhibitor of cholesterol binding to LAMP1.


1115899-15-4 A novel small-molecule arenaviruse inhibitor that exhibits strong anti-LCMV activity (IC50<1 uM) without cell toxicity; inhibits LCMV cell entry by specifically interfering with the pH-dependent fusion in the endosome compartment that is mediated by LCMV glycoprotein GP2; inhibits LCMV multiplication with IC50 of 0.4, 0.7 and 0.9 uM in A549 BHK-21 and Vero cells, respectively.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us